GSK (GSK) Competitors

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Do analysts prefer AZN or GSK?

AstraZeneca currently has a consensus target price of GBX 6,303.50, suggesting a potential downside of 41.38%. GSK has a consensus target price of GBX 1,805.83, suggesting a potential upside of 21.81%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Which has better valuation and earnings, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£66.95B	3.09	£8.71B	£364.83	29.47
GSK	£31.14B	1.93	£2.50B	£61.91	23.95

Do institutionals and insiders have more ownership in AZN or GSK?

51.0% of AstraZeneca shares are held by institutional investors. Comparatively, 45.3% of GSK shares are held by institutional investors. 0.0% of AstraZeneca shares are held by company insiders. Comparatively, 1.6% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is AZN or GSK a better dividend stock?

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.0%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Is AZN or GSK more profitable?

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	13.01%	17.76%	7.68%
GSK	8.02%	18.08%	9.56%

Does the media prefer AZN or GSK?

In the previous week, AstraZeneca and AstraZeneca both had 9 articles in the media. GSK's average media sentiment score of 0.37 beat AstraZeneca's score of 0.24 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, AZN or GSK?

AstraZeneca has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.

Does the MarketBeat Community favor AZN or GSK?

AstraZeneca received 773 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.77% of users gave AstraZeneca an outperform vote while only 50.37% of users gave GSK an outperform vote.

Company	Underperform	Outperform
AstraZeneca	Outperform Votes 1864 63.77%	Underperform Votes 1059 36.23%
GSK	Outperform Votes 1091 50.37%	Underperform Votes 1075 49.63%

Summary

AstraZeneca beats GSK on 11 of the 19 factors compared between the two stocks.